positron emission tomography; fluorinated tracers; cancer imaging; fluorothymidine
Abstract :
[en] Positron emission tomography (PET) with {F-18}-FDG is nowfirmly established as a clinical tool in oncology. Its applications are however limited in some indications, due to the lack of specificity of its uptake mechanism for tumors, or the low avidity of some cancer types such as prostate. Alternative tracers are thus being developed, in order to fill up this void. Proliferation as a biological target is particularly attractive in cancer imaging. From that perspective, fluorothymidine ({F-18}-FLT or FLT) has generated a strong interest among the scientific community, especially since the radiosynthesis process has been improved and simplified, thus making possible to envision a routine use for the tracer. This article aims at summarizing the status of the current scientific data regarding FLT The uptake mechanism of FLT is well known, relying on the thymidine kinase 1 (TK1) enzymatic activity, and thus on DNA synthesis, Preclinical studies have shown a clear relationship between tracer accumulation and level of tumor proliferation, even though DNA salvage pathwayss intervene in the process and may complicate the interpretation of the results. Several clinical studies suggest a good specificity for tumor, albeit with a lower sensitivity than with FDG. In all likelihood however, the future of FLT lies in the evaluation of antitumor response and possibly the pretherapeutic prognostic characterization, rather than in the diagnosis and staging of malignancies. Although the scientific data regarding this issue remain limited, initial results are encouraging. Further significant work remains to he done in order to fully assess the clinical performances of the tracer, on the one hand, and to determine its place relative to FDG and other emerging tracers, on the other hand. Until these studies are completed, FLT should he considered as a promising tracer, hut remaining at an experimental stage of its development.
Disciplines :
Oncology
Author, co-author :
Couturier, Olivier; Inserm U601 (Nantes)
Léost, Françoise; Inserm U601 (Nantes)
Campone, Mario; Centre René Gauducheau
Carlier, Thomas; Inserm U601 (Nantes)
Chatal, Jean-François; Inserm U601 (Nantes)
Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire
Language :
French
Title :
Is 3 '-deoxy-3 '-[F-18] fluorothymidine ([F-18]-FLT) the next tracer for routine clinical PET after R [F-18]-FDG?
Senekowitsch-Schmidtke, R., Rüth, F., Bernatz, S., Radiolabeled thymidine: A sensitive tracer for early tumor response and recurrence after irradiation (1999) J Nucl Med, 40, pp. 1702-1705
Eary, J., Mankoff, D., Spence, A., 2-[C-11] thymidine imaging of malignant brain tumors (1999) Cancer Res, 59, pp. 615-621
Martiat, P., Ferrant, A., Labar, D., In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography (1988) J Nucl Med, 29, pp. 1633-1637
Shields, A., Mankoff, D., Link, J., Carbon-11-thymidine and FDG to measure therapy response (1998) J Nucl Med, 39, pp. 1757-1762
Van Eijkeren, M.E., De Schryver, A., Goethals, P., Measurement of short-term 11C-thymidine activity in human head and neck tumours using positron emission tomography (PET) (1992) Acta Oncol, 31, pp. 539-543
Vander Borght, T., Pauwels, S., Lambotte, L., Brain tumor imaging with PET and 2-[carbon-11] thymidine (1994) J Nucl Med, 25, pp. 974-982
Tjuvajev, J., Maruki, A., Ginos, J., Iododeoxyuridine (IUDR) uptake and retention as a mesure of tumor growth (1993) J Nucl Med, 34, pp. 1152-1161
Tjuvajev, J., Macapinlac, H., Daghighian, F., Imaging of the brain tumor proliferative activity with [131I] iododeoxyuridine (1994) J Nucl Med, 35, pp. 1407-1417
Blasberg, R., Roelcke, U., Weinreich, B., Imaging brain tumor proliferative activity with [124I] iododeoxyuridine (2000) Cancer Res, 60, pp. 624-635
Mankoff, D.A., Shields, A.F., Graham, M.M., Kinetic analysis of 2-[carbon-11] thymidine PET imaging studies: Compartmental model and mathematical analysis (1998) J Nucl Med, 39, pp. 1043-1055
Nimmagadda, S., Mangner, T.J., Muzik, O., Metabolic studies of F-18-FBAU in dogs: A PET tracer for DNA synthesis (2002) J Nucl Med, 43, p. 94
Wang, H., Oliver, P., Nan, L., Radiolabeled 2′-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice (2002) Cancer Chemother Pharmacol, 49, pp. 419-424
Flexner, C., Van Der Horst, C., Jacobson, M.A., Relationship between plasma concentrations of 3′-deoxy-3′- fluorothymidine (alovudine) and anti-retroviral activity in two concentration-controlled trials (1994) J Infect Dis, 170, pp. 1394-1403
Wilson, I.K., Chatterjee, S., Wolf, W., Synthesis of 3′-fluoro-3′-deoxythymidine and studies of its 18F-radiolabeling, as a tracer for the noninvasive monitoring of the biodistribution of drugs against AIDS (1991) J Fluorine Chem, 55, pp. 283-289
Grierson, J., Shields, A.F., Eary, J.F., Development of a radiosynthesis for 3′-[F-18] fluoro-3′- deoxynucleosides (1997) J Labelled Compound Radiopharmaceuticals, 40, pp. 60-62
Grierson, J.R., Shields, A.F., Radiosynthesis of 3′-deoxy-3′-[(18)F] fluorothymidine: [(18)F] FLT for imaging of cellular proliferation in vivo (2000) Nucl Med Biol, 27, pp. 143-156
Martin, S., Eisenbarth, J., Wagner-Utermann, U., [18F] FLT: 18F labeling of 3-Boc-1-(2-deoxy-3-O-nosyl-5-O-trityl-b-D- lyxofuranosyl) thymine and other thymine derivatives (2000) J Nucl Med, p. 41
Martin, S., Eisenbarth, J., Wagner-Utermann, U., A new precursor for the radiosynthesis of [18F] FLT (2002) Nucl Med Biol, 29, pp. 263-273
Yun, M., Oh, S.J., Ha, H.J., High radiochemical yield synthesis of 3′-deoxy-3′-[18F] fluorothymidine using (5′-O-dimethoxytrityl-2′-deoxy-3′-O- nosyl-beta-D-threo pentofuranosyl) thymine and its 3-N-BOC-protected analogue as a labeling precursor (2003) Nucl Med Biol, 30, pp. 151-157
Oh, S.J., Mosdzianowski, C., Chi, O.Y., Fully automated synthesis system of 3′-deoxy-3′-[18F] fluorothymidine (2004) Nucl Med Biol, 31, pp. 803-809
Belt, J., Marina, N., Phelps, O., Nucleoside transport in normal and neoplastic tells (1993) Adv Enzyme Regal, 33, pp. 235-252
Plagemann, P.G., Richey, D.P., Zylka, J.M., Thymidine transport by Novikoff rat hepatoma cells synchronized by double hydroxyurea treatment (1974) Exp Cell Res, 83, pp. 303-310
Schwartz, J.L., Tamura, Y., Jordan, R., Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs (2003) J Nucl Med, 11, pp. 2027-2032
Toyohara, J., Waki, A., Takamatsu, S., Basis of FLT as cell proliferation marker: Comparative uptake studies with [3H] thymidine and [3H] arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines (2002) Nucl Med Biol, 29, pp. 281-287
Lu, L., Samuelsson, L., Bergstrom, M., Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers (2002) J Nucl Med, 43, pp. 1688-1698
Wagner, M., Seitz, U., Buck, A., 3′-[18F] fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease (2003) Cancer Res, 63, pp. 2681-2687
Seitz, L.J., Wagner, M., Neumaier, B., Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F] fluoro-3′-deoxythymidine ([(18)F] FLT) in pancreatic cancer cell lines (2002) Eur J Nucl Med Mol Imaging, 29, pp. 1171-1181
Sundseth, R., Joyner, S.S., Moore, J.T., The anti-human immunodeficiency virus agent 3′-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells (1996) Antimicrob Agents Chemother, 40, pp. 331-335
Kong, X.B., Zhu, Q.Y., Vidal, P.M., Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro- 3′-deoxythymidine and 3′-azido-3′-deoxythymidine (1992) Antimicrob Agents Chemother, 36, pp. 808-818
Grierson, J.R., Schwartz, J.L., Muzi, M., Metabolism of 3′-deoxy-3′-[F-18] fluorothymidine in proliferating A549 cells: Validations for positron emission tomography (2004) Nucl Med Biol, 31, pp. 829-837
Rasey, J., Grierson, J., Wiens, L., Uptake of labeled FLT correlates with thymidine kinase (TK1) activity in human tumor cells (2000) J Nucl Med, 41 (SUPPL.), pp. P36-P37
Barthel, H., Perumal, M., Latigo, J., The uptake of 3′-deoxy-3′-[(18)F] fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels (2005) Eur J Nucl Med Mol Imaging, 32, pp. 257-263
Sorensen, P., Wintersberger, E., Sp1 and NF-Y are necessary and sufficient for growth-dependent regulation of the hamster thymidine kinase promoter (1999) J Biol Chem, 274, pp. 30943-30949
Bartrek, J., Bartkova, J., Lukas, J., The retinoblastoma protein pathway and the restriction point (1996) Current Opin Cell Biol, 8, pp. 805-814
Ewen, M., The cell cycle and the retinoblastoma protein family (1994) Cancer Metastasis Rev, 13, pp. 45-66
Sherr, C., Roberts, J., Inhibitors of mammalian G1 cycline-dependent kinases (1995) Genes Dev, 9, pp. 1149-1163
Weinberg, R., The retinoblastoma protein and cell cycle control (1995) Cell, 81, pp. 323-330
Buchmann, I., Neumaier, B., Schreckenberger, M., [18F] 3′-deoxy-3′-fluorothymidine-PET in NHL patients: Whole-body biodistribution and imaging of lymphoma manifestations: A pilot study (2004) Cancer Biother Radiopharm, 19, pp. 436-442
Hengstchlager, M., Hengstshlager-Ottnad, E., Oliver, P., The role of p16 in the E2F-dependent thymidine kinase regulation (1996) Oncogene, 12, pp. 1635-1643
Hengstchlager, M., Knofler, M., Mullner, E., Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells (1994) J Biol Chem, 269, pp. 13836-13842
Hengstchlager, M., Oliver, P., Hengstshlager-Ottnad, E., Loss of the p16/MTS1 tumor suppressor gene causes E2F-mediated deregulation of essential enzymes of the DNA precursor metabolism (1996) DNA Cell Biol, 15, pp. 41-51
Coppock, D., Pardee, A., Control of thymidine kinase mRNA during the cell cycle (1987) Mol Cell Biol, 7, pp. 2925-2932
Gross, M., Merrill, G., Regulation of thymidine kinase protein levels during myogenic withdrawal from the cell cycle is independent of mRNA regulation (1988) Nucleic Acids Res, 16, pp. 11625-11643
Sherley, J., Kelly, T., Regulation of human thymidine kinase during the cell cycle (1988) J Biol Chem, 263, pp. 8350-8358
Ito, M., Conrad, S., Independent regulation of thymidine kinase mRNA and enzyme levels in serum-stimulated cells (1990) J Biol Cbem, 265, pp. 6954-6960
Rasey, J.S., Grierson, J.R., Wiens, L.W., Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells (2002) J Nucl Med, 43, pp. 1210-1217
Buck, A.K., Halter, G., Schirrmeister, H., Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG (2003) J Nucl Med, 44, pp. 1426-1431
Wells, P., Gunn, R.N., Alison, M., Assessment of proliferation in vivo using 2-[(11)C] thymidine positron emission tomography in advanced intra-abdominal malignancies (2002) Cancer Res, 62, pp. 5698-5702
Dittmann, H., Dohmen, B.M., Kehlbach, R., Early changes in [18F] FLT uptake after chemotherapy : An experimental study (2002) Eur J Nucl Med Mol Imaging, 29, pp. 1462-1469
Barthel, H., Cleij, M.C., Collingridge, D.R., 3′-deoxy-3′-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography (2003) Cancer Res, 63, pp. 3791-3798
Oyama, N., Ponde, D.E., Dence, C., Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation (2004) J Nucl Med, 45, pp. 519-525
Sugiyama, M., Sakahara, H., Sato, K., Evaluation of 3′-deoxy-3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice (2004) J Nucl Med, 45, pp. 1754-1758
Waldherr, C., Mellinghoff, I.K., Tran, C., Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET (2005) J Nucl Med, 46, pp. 114-120
Kubota, R., Kubota, K., Yamada, S., Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography (1992) J Nucl Med, 33, pp. 1972-1980
Brown, R.S., Leung, J.Y., Fisher, S.J., Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? (1995) J Nucl Med, 36, pp. 1854-1861
Higashi, K., Clavo, A.C., Wahl, R.L., In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy (1993) J Nuclear Med, 34, pp. 773-779
Lewis, P., Salama, A., Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis (1994) J Nucl Med, 35, pp. 1647-1649
Minn, H., Clavo, A.C., Grenman, R., In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck (1995) J Nuclear Med, 36, pp. 252-258
Patz Jr., E.F., Lowe, V.J., Hoffman, J.M., Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning (1993) Radiology, 188, pp. 487-490
Wilmore, D.W., Aulick, L.H., Mason, A.D., Influence of the burn wound on local and systemic responses to injury (1977) Ann Surg, 186, pp. 444-458
Sugawara, Y., Gutowski, T.D., Fisher, S.J., Uptake of positron emission tomography tracers in experimental bacterial infections: A comparative biodistribution study of radiolabeled FDG, thymidine, L-methionine, 67Gacitrate, and 125I-HSA (1999) Eur J Natl Med, 26, pp. 333-341
Scharko, A.M., Perlman, S.B., Hinds, P., Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques (1996) Proc Natl Acad Sci USA, 93, pp. 6425-6430
Wahl, R.L., Fisher, S.J., A comparison of FDG, L-methionine and thymidine accumulation into experimental infections and reactive lymph nodes (1993) J Nucl Med, 34, pp. 104P
Van Waarde, A., Cobben, D.C., Suurmeijer, A.J., Selectivity of (18) F-FLT and (18) F-FDG for differentiating tumor from inflammation in a rodent model (2004) J Nucl Med, 45, pp. 695-700
Carter, E.A., McKuster, K., Syed, S., Comparison of (FLT)-F-18 with (18) FDG for differentiation between tumor and focal sites of infection in rats (2002) J Nuclear Med, 43, p. 1074
Shields, A.F., Grierson, J.R., Dohmen, B.M., Imaging proliferation in vivo with [F-18] FLT and positron emission tomography (1998) Nature Med, 4, pp. 1334-1336
Vesselle, H., Grierson, J., Peterson, L.M., 18F-fluorothymidine radiation dosimetry in human PET imaging studies (2003) J Nucl Med, 44, pp. 1482-1488
Buck, A.K., Schirrmeister, H., Hetzel, M., 3-Deoxy-3- [18] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules (2002) Cancer Res, 62, pp. 3331-3334
Francis, D.L., Freeman, A., Visvikis, D., In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography (2003) Gut, 52, pp. 1602-1606
Visvikis, D., Francis, D., Mulligan, R., Comparison of methodologies for the in vivo assessment of (18) FLT utilisation in colorectal cancer (2004) Eur J Nucl Med Mol Imaging, 25, pp. 637-641
Vesselle, H., The biology of lung cancer- FDG and fluorothymidine PET (2004) Academic Radiology, 11, pp. E27
Halter, G., Buck, A.K., Schirrmeister, H., [F] 3-deoxy-3′-fluorothymidine positron emission tomography: Alternative or diagnostic adjunct to 2-[F]-fluoro-2-deoxy-d-glucose positron emission tomography in the workup of suspicious central focal lesions? (2004) J Thorac Cardiovasc Surg, 127, pp. 1093-1099
Dittmaim, H., Dohmen, B.M., Paulsen, F., [18F] FLT PET for diagnosis and staging of thoracic tumours (2003) Eur J Nucl Med Mol Imaging, 30, pp. 1407-1412
Cobben, D.C., Elsinga, P.H., Hoekstra, H.J., Is 18F-3′-fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? (2004) J Nucl Med, 45, pp. 1677-1682
Francis, D.L., Visvikis, D., Costa, D.C., Potential impact of [18F] 3′-deoxy-3′-fluorothymidine versus [18F] fluoro-2-deoxy-D-glucose in positron emission tomography forcolorectal cancer (2003) Eur J Nucl Med Mol Imaging, 30, pp. 988-994
Cobben, D.C., Jager, P.L., Elsinga, P.H., 3′-18F-fluoro-3′-deoxy-L-thymidine: A new tracer for staging metastatic melanoma? (2003) J Nucl Med, 44, pp. 1927-1932
Cobben, D.C., Van Der Laan, B.F., Maas, B., 18F-FLT PET for visualization of laryngeal cancer: Comparison with 18F-FDG PET (2004) J Nucl Med, 45, pp. 226-231
Cobben, D.C., Elsinga, P.H., Suurmeijer, A.J., Detection and grading of soft tissue sarcomas of the extremities with (18) F-3′-fluoro-3′-deoxy-L-thymidine (2004) Clin Cancer Res, 10, pp. 1685-1690
Choi, S.J., Kim, J.S., Kim, J.H., [(18)F] 3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors (2005) Eur J Nucl Med Mol Imaging, , in press
Smyczek-Gargya, B., Fersis, N., Dittmann, H., PET with [(18)F] fluorothymidine for imaging of primary breast cancer: A pilot study (2004) Eur J Nucl Med Mol Imaging, 31, pp. 720-724
Van Westreenen, H.L., Cobben, D.C., Jager, P.L., Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer (2005) J Nucl Med, 46, pp. 400-404
Shields, A.F., Dohmen, B.M., Mangner, T.J., Use of F-18-FLT for imaging gastrointestinal tumors (2001) J Nucl Med, 42, p. 108
Dohmen, B.M., Shields, A.F., Dittmann, H., Use of (FFLT)-F-18 for breast cancer imaging (2001) J Nuclear Med, 42, p. 107
Pio, B.S., Park, C.K., Satyamurthy, N., PET with fluoro-L-thymidine allows early prediction of breast cancer response to chemotherapy (2003) J Nucl Med, 44, pp. 76P
Couturier, O., Bodet-Milin, C., Cherel, M., Fluorinated tracers for imaging tumoral proliferation with positron emission tomography (2004) Médecine Nucléaire, 28, pp. 371-375
Couturier, O., Chatal, J.-F., Hustinx, R., Fluorinated analogs of nucleosides and fluorinated tracers of gene expression for positron emission tomography (2004) Bull Cancer, 91, pp. 695-703
